TrialEvaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Trial details
- Registry ID
- NCT05714345
- Phase
- Phase 2
ALLO
Allogene Therapeutics
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell TherapyNCT05714345 | Allogene Therapeutics | Phase 2 | Terminated | 2024-02-20Actual |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLNCT06500273 | Allogene Therapeutics | Phase 2 | Recruiting | 2027-12Estimated |
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Trial details
- Registry ID
- NCT06500273
- Phase
- Phase 2
Latest recorded trial changes
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273 · Allogene Therapeutics
Primary completion date
Recorded edit− Previous value
2027-08-24
+ Updated value
2027-12
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
NCT05714345 · Allogene Therapeutics
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: To assess the clinical efficacy of ALLO-647 (in a lymphodepletion regimen before ALLO-501A) compared to FC alone as measured by PFS and assessed by IRC in subjects with R/R (Relapsed / Refractory) LBCL (Large B Cell Lymphoma)
+ Updated value
measure: Progression-Free Survival (PFS) of a Lymphodepletion Regimen Containing FCA vs FC Alone Per Independent Review Committee
The saved outcome text may be shortened. Check the source for full wording.
Participant count type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Enrollment · participant count
Recorded edit− Previous value
count: 70; type: ESTIMATED
+ Updated value
count: 2; type: ACTUAL
Recruitment status
Recorded edit− Previous value
Active not recruiting
+ Updated value
Terminated